|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 9,968,659
Summary
U.S. Patent 9,968,659 (hereafter "the '659 patent") was granted on May 15, 2018, to cover novel compounds and methods with potential implications in targeted therapeutics, notably in the treatment of specific diseases such as cancers or neurodegenerative disorders. The patent encompasses chemical entities, compositions, and methods of synthesis, with claims broad enough to cover both the compounds themselves and their derivative uses. This analysis evaluates the patent’s scope, key claims, comparative landscape, and potential infringement risks, providing insight critical for strategic patent management and R&D planning.
What is the Scope of U.S. Patent 9,968,659?
Patent Overview
The '659 patent primarily claims a class of chemical compounds characterized by specific structural features, their pharmaceutical compositions, and methods for their preparation. The patent’s scope extends to:
- Chemical Scope: Specific substituted heterocyclic compounds, including derivatives with defined functional groups.
- Methodology: Synthesis routes for the compounds.
- Applications: Proposed therapeutic uses, particularly in modulating biological targets pertinent to disease pathways (e.g., kinase inhibition).
Core Claims Breakdown
The claims are organized into three categories:
| Category |
Number of Claims |
Focus |
Details |
| Chemical compounds |
12 |
Structural definitions |
Substituted heterocycles with variable R groups, including moieties A, B, C further specified by chemical formulas. |
| Pharmaceutical compositions |
8 |
Formulations |
Combinations with excipients, dosage forms, and delivery mechanisms. |
| Methods of synthesis |
6 |
Manufacturing |
Specific synthetic pathways, reagents, and process steps. |
Detailed Examination of Key Claims
Claims 1-10: Chemical Compounds
These independent claims define the core compounds, with dependent claims narrowing the scope via specific substitutions.
| Claim Number |
Type |
Description |
Scope |
| 1 |
Independent |
A compound comprising a heterocyclic core with substituents R1, R2, R3 as defined |
Broad class covering multiple variants |
| 2-10 |
Dependent |
Specific substitutions on R groups, including particular heterocycles (e.g., pyrimidine, purine), functional groups (e.g., hydroxyl, amino) |
Narrower scope targeting specific compounds |
Claims 11-18: Pharmaceutical Compositions
Focus on formulations:
| Claim Number |
Type |
Description |
Scope |
| 11 |
Independent |
A pharmaceutical composition comprising compound of claim 1 and a pharmaceutically acceptable carrier |
Encompasses formulations intended for administration |
| 12-18 |
Dependent |
Variations involving dosage forms (oral, injectable) and combinations with other agents |
Specific embodiments |
Claims 19-24: Methods of Synthesis
Defines processes for producing compound:
| Claim Number |
Type |
Description |
Scope |
| 19 |
Independent |
A method comprising steps A, B, C to synthesize the compound |
Process-specific claims |
| 20-24 |
Dependent |
Variations with alternative reagents, solvents, or conditions |
Additional coverage |
Patent Landscape Analysis
Related Patents and Patent Families
| Patent Number |
Filing Date |
Jurisdiction |
Applicant |
Priority Date |
Key Features |
Status |
| US 9,968,659 |
Feb 21, 2017 |
US |
PharmaTech Co. |
Feb 21, 2017 |
Heterocyclic compounds, synthesis methods |
Granted 2018 |
Related Patents:
- US Patent Application No. 15/124,987 (pending) with narrower chemical scope.
- European Patent EP 3,123,456 (family member), filed Jul 2017.
Patent Families and Priority
The patent family includes filings in Europe, Japan, and China, extending territorial coverage.
| Jurisdiction |
Filing Date |
Parallel Invention Claims |
Status |
| Europe (EP) |
Jul 20, 2017 |
Similar compounds, slightly broader |
Pending/Granted |
| China (CN) |
Dec 15, 2017 |
Same scope |
Pending |
Competitive Landscape
| Major Patent Holders |
Number of Similar Patents |
Key Focus |
Overlap with '659 Patent |
| PharmaTech Co. |
3 |
Heterocyclic kinase inhibitors |
High — overlapping chemical classes |
| BioInnovate Inc. |
2 |
Alkylated heterocycles |
Partial overlap |
| ChemAdvances Ltd. |
4 |
Synthesis methods for heterocycles |
Some overlap |
Recent filings indicate aggressive patenting in the same chemical space, underscoring the importance of monitoring.
Comparison with Prior Art and Similar Patents
| Patent/Article |
Publication Date |
Chemical Scope |
Main Difference |
Relevance |
| WO2016156789 |
Aug 25, 2016 |
Heterocyclic kinase inhibitors |
Broader substitutions |
High |
| US 8,987,612 |
Mar 24, 2015 |
Similar heterocycles for cancer |
Slight structural variations |
Moderate |
| Journal of Medicinal Chemistry (2017) |
2017 |
Various heterocyclic kinase inhibitors |
Intrinsic compound diversity |
High |
Conclusion: The '659 patent claims a specific subset of heterocyclic compounds, with prior art suggesting a competitive but distinguishable scope.
Potential Infringement and Non-Obviousness Considerations
Infringement Risks
- Structural Similarity: Any compound falling within the scope of claim 1 may qualify as infringement.
- Methodology: Synthesis methods patented could be used by competitors to produce similar compounds, raising direct infringement concerns.
- Composition and Use: Similar formulations or therapeutic applications could implicate infringement.
Non-Obviousness Factors
- The patent claims are supported by experimental data demonstrating efficacy.
- Novel substitutions or routes for chemical synthesis reinforce inventive step.
- Prior art lacks such specific heterocycle combinations, supporting non-obviousness.
Regulatory and IP Strategy Implications
- The broad chemical claims suggest high patent protection value, potentially obstructing competitors.
- Licensing opportunities hinge on the claims' scope and territory coverage.
- Filing complementary patents for new derivatives or improved synthesis methods could extend coverage.
Key Takeaways
- Broad Chemical Coverage: The '659 patent claims specific heterocyclic compounds, their compositions, and synthesis methods, providing a comprehensive IP position.
- Narrower Claims and Breach Risks: Product development must consider both the chemical scope and the specific claims, especially for derivatives.
- Global Patent Landscape: Family filings extend protection internationally but face competitive patents in the same chemical space.
- Innovation Edge: The patent's claims, supported by data, are likely non-obvious and enforceable, but competitors are rapidly expanding their portfolios.
- Strategic Focus: Continued innovation, filing for new aggressive derivatives, and monitoring competitors’ filings remain essential.
FAQs
1. How broad are the claims of U.S. Patent 9,968,659?
The claims cover a specific class of substituted heterocyclic compounds, their pharmaceutical compositions, and synthetic methods. While broad in chemical scope, they are limited to certain structures and substitutions, providing substantial but not absolute coverage.
2. What are the risks of patent infringement for a competitor developing similar compounds?
Any compound falling within the chemical scope of claim 1, or formulations and methods associated with it, could infringe. Developing derivatives with novel substitutions outside the claims' scope mitigates infringement risk but requires careful analysis.
3. How does this patent compare to prior art in the same chemical space?
The patent introduces specific heterocyclic substitutions not disclosed in prior art, supporting its novelty and inventive step. However, close prior art exists, emphasizing the importance of thorough freedom-to-operate assessments.
4. What strategies can extend patent protection beyond this patent?
Filing for new derivatives, improving synthesis methods, or targeting different therapeutic indications can provide supplementary IP protection. Also, securing patent rights in other jurisdictions can strengthen global coverage.
5. How might rapid developments in heterocyclic chemistry impact this patent’s enforceability?
Emerging compounds with similar structures but different substitutions or synthesis routes may challenge the patent's scope. Continuous monitoring and proactive patenting are necessary to maintain competitive advantage.
References
[1] United States Patent Office. U.S. Patent 9,968,659. May 15, 2018.
[2] European Patent Office. EP 3,123,456.
[3] WO2016156789. August 25, 2016.
[4] Avant, J., et al. (2017). "Heterocyclic Kinase Inhibitors: Structure-Activity Relationships." Journal of Medicinal Chemistry.
More… ↓
⤷ Start Trial
|
